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Background: Emerging evidence suggests that innate immunity and increased oxidative stress contribute to
pathomechanisms in amyotrophic lateral sclerosis (ALS). The aim of the present study was to verify the involvement
of monocyte chemoattractant protein-1 (MCP-1) and its specific CC chemokine receptor 2 (CCR2) in the disease
progression of ALS. We here demonstrate the expression state of MCP-1 and CCR2 in lumbar spinal cords of mice
overexpressing a transgene for G93A mutant human superoxide dismutase 1 (SOD1) (ALS mice) as a mouse model
of ALS as well as the involvement of MCP-1/CCR2-mediated signaling in behavior of cultured astrocytes derived
from those mice.
Results: Quantitative polymerase chain reaction analysis revealed that MCP-1 and CCR2 mRNA levels were
significantly higher in ALS mice than those in nontransgenic littermates (control mice) at the presymptomatic stage.
Immunoblot analysis disclosed a significantly higher CCR2/β-actin optical density ratio in the postsymptomatic ALS
mouse group than those in the age-matched control mouse group. Immunohistochemically, MCP-1 determinants
were mainly localized in motor neurons, while CCR2 determinants were exclusively localized in reactive astrocytes.
Primary cultures of astrocytes derived from ALS mice showed a significant increase in proliferation activity under
recombinant murine MCP-1 stimuli as compared to those from control mice.
Conclusions: Our results provide in vivo and in vitro evidence that MCP-1 stimulates astrocytes via CCR2 to induce
astrocytosis in ALS with SOD1 gene mutation. Thus, it is likely that MCP-1/CCR2-mediated sigaling is involved in the
disease progression of ALS.
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Amyotrophic lateral sclerosis (ALS) is a late onset neuro-
degenerative disease characterized by a progressive and
selective loss of motor neurons in the motor cortex, brain
stem motor nuclei, and spinal cord ventral horns [1].
Patients affected with ALS develop progressive muscle
weakness associated with neurogenic amyotrophy, and
they will die of respiratory failure within 3–5 years un-
less undergoing artificial ventilation [2]. Approximately
10% of the ALS patients are familial. About 20% of the
familial ALS patients are associated with mutations in
the gene for superoxide dismutase 1 (SOD1) [1]. Mice* Correspondence: mnkawa@research.twmu.ac.jp
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demonstrate clinicopathological features resembling hu-
man ALS [3]. Thus, mutant human SOD1 transgenic
mice have been used in a large number of studies on
ALS as an outstanding animal model of ALS.
Although the complete pathomechanism of ALS has
not yet been understood, several studies have obtained
evidence that inflammatory processes, including increased
levels of proinflammatory cytokines and proliferation
and activation of glial cells in the main lesions, are in-
volved in the disease progression [4]. Actually, our pre-
vious report showed increased levels of activated form
of p38 mitogen-activated protein kinase (MAPK) and
reduced levels of inhibitor of kappa B-alpha (IκBα) in
G93A mutant SOD1 transgenic mice as well as a benefi-
cial effect of pioglitazone, an antiinflammatory agent ofd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,


































































Figure 1 RT-qPCR analysis for MCP-1 and CCR2 mRNA in the
spinal cord of mice. MCP-1 (a) and CCR2 (b) mRNA levels normalized
with GAPDH mRNA levels are compared between SJL (gray columns)
and G1H+/− (black columns) mice sacrificed at presymptomatic (9 w),
onset (12 w), and postsymptomatic (15 w) stages (n = 6 in each group).
Two-way ANOVA provides P < 0.05. Posthoc Bonferroni correction
provides #P < 0.05 and $P < 0.01 as compared to the presymptomatic
and onset G1H+/− groups and *P < 0.01 and †P < 0.001 as compared
to the age-matched SJL groups.
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peroxisome proliferator-activated receptor gamma, on
survival of motor neurons and suppression of glial acti-
vation through inhibition of p38 MAPK activation and
upregulation of IκBα expression [5].
As reviewed by Conductier et al., several investiga-
tions have demonstrated implications for monocyte
chemoattractant protein-1 (MCP-1), a synonym of CC
chemokine ligand 2 (CCL2), in neurological disorders
[6]. MCP-1, an 8 kDa secretory protein, is released from
certain cells to exert a potent proinflammatory effect on
its target cells by binding to the specific receptor CCR2
[7]. MCP-1/CCR2-mediated signaling drives the down-
stream phosphatidylinositol-3 kinase/Akt and MAPK
pathways [8-10]. It is known that MCP-1 induces
chemotaxis of macrophages and microglia, leading to
pathological microgliosis and inflammatory activation in
the lesions [11]. This is supported by a number of stud-
ies showing that MCP-1 knockout mice are resistant to
stroke and autoimmune encephalomyelitis [12,13].
Recent studies have suggested implications for MCP-1
in ALS. Increased levels of MCP-1 in serum or cerebro-
spinal fluid of sporadic and familial ALS patients [14-18]
or spinal cord tissue samples from mutant SOD1 trans-
genic mice [19,20] have been reported. On the other hand,
it is of interest that CCR2 expression levels on the
cell surface of circulating monocytes in sporadic ALS
patients were very low [21,22]. However, the role of
CCR2 in a mouse model of ALS remains to be deter-
mined. To address this issue, we evaluated the expression
state of CCR2 as well as MCP-1 in the spinal cord of
mutant human SOD1 transgenic mice, by quantitative and
morphological approaches using a reverse transcription-
quantitative polymerase chain reaction (RT-qPCR), immu-
nohistochemistry, and immunoblotting techniques. We
also evaluated in vitro effects of MCP-1 using primary cul-
tures of astrocytes derived from the transgenic mice and
nontransgenic littermates.
Results
MCP-1 and CCR2 mRNA levels are changed in the spinal
cord of ALS mice
Using RT-qPCR techniques, expression levels of MCP-1
and CCR2 mRNA in lumbar spinal cords from G1H+/−
(ALS mice) and SJL (control mice) mice were quantitatively
compared between the presymptomatic (9-weeks-old mice),
onset (12-weeks-oldmice), and postsymptomatic (15-weeks-
oldmice) groups. MCP-1 mRNA analysis revealed clear
results (Figure 1a). In all of these stages, MCP-1 mRNA
levels were significantly higher in the G1H+/− groups
than those in the age-matched SJL groups and age-
dependently increased in the G1H+/− groups but not the
SJL groups. On the other hand, CCR2 mRNA analysis
revealed complicated results (Figure 1b). CCR2 mRNAlevels were significantly higher in the presymptomatic and
onset G1H+/− groups than those in the age-matched SJL
groups, whereas there was no significant difference in the
levels between the postsymptomatic G1H+/− group and
the age-dependent SJL group. In G1H+/− mice, CCR2
mRNA levels tended to be higher in the onset group than
that in the presymptomatic group, and were significantly
lower in the postsymptomatic group than in the other
groups. By contrast, SJL mice showed constant CCR2
mRNA levels among the three stage groups.
MCP-1 protein is mainly expressed in spinal cord motor
neurons of ALS mice
MCP-1 immunohistochemistry made a striking con-
trast between G1H+/− and SJL mice (Figure 2). While




Figure 2 Immunohistochemical observations of MCP-1 protein
in the spinal cord of SJL and G1H+/− mice sacrificed at
presymptomatic (9 w) and postsymptomatic (15 w) stages
(n = 3 in each group). Inset indicates a vacuolated neuron.
Immunoreaction product deposits are visualized by the avidin-biotin
-immunoperoxidase complex method using 3,3’-diaminomenzidine
tetrahydrochloride and hematoxylin as the chromogen and
counterstain, respectively, by light microscopy. Scale bars indicate
100 μm (panels) and 50 μm (inset).
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or not at all in the age-matched SJL mice. In G1H+/−
mice, immunoreactivity was mainly detectable in the
cytoplasm of motor neurons, was more intense in the
postsymptomatic group, and was prominent in vacuolated
neurons, in particular, but was very weak in glial cells.CCR2 protein is mainly expressed in spinal cord reactive
astrocytes of ALS mice
CCR2 immunoreactivity also showed distinct alterations
between SJL and G1H+/− mice (Figure 3a). The immu-
noreactivity was only very weak in young to old SJL
mice and presymptomatic G1H+/− mice. By contrast, it
was highly intense in onset and postsymptomatic G1H
+/− mice, and was particularly prominent in glial cells,
but was undetectable in neurons. To identify CCR2-
immunoreactive cells, we performed double-labeled
immunofluorescence staining of sections from G1H
+/− mice at onset stage. CCR2 immunoreactivity was
detected in almost all GFAP-immunoreactive astro-
cytes (Figure 4d-f; g-i), whereas it was detected in only a
few NeuN-immunoreactive neurons (Figure 4a-c) and
Iba-1 or CD11b-immunoreactive microglia (Figure 4j-l;
m-o). There was no significant difference in staining pat-
terns between the two different anti-CCR2 antibodies.
These results were confirmed by quantitative image ana-
lysis; the great majority of CCR2-immunoreactive cells inspinal cord ventral horns were astrocytes but not neurons
or microglia (Figure 5).
CCR2 protein levels are increased in the spinal cord of
ALS mice
Expression levels of CCR2 protein in lumbar spinal cords
were quantitatively compared between the postsymp-
tomatic SJL and G1H+/− groups. Immunoblot analysis
disclosed CCR2-immunoreactive signals, prominent in the
G1H+/− group, at a mobility of 42 kDa (Figure 3b). Densi-
tometric analysis revealed that immunoreactive signals for
CCR2 normalized with those for β-actin were significantly
higher in the G1H+/− group than in the age-matched SJL
group (Figure 3c).
rmMCP-1 induces proliferation of cultured astrocytes
derived from ALS mice via CCR2
Using primary cultures, we compared effects of MCP-1 on
the proliferative activity of primary astrocytes derived
from SJL and G1H+/− mice, as determined by a CCK-8
kit. In the absence of rmMCP-1, the basal levels of prolif-
eration activity of astrocytes were significantly increased
in the G1H+/− group as compared to the SJL group. In
the presence of rmMCP-1, the levels exhibited a dose-
dependent increase in the G1H+/− groups but not the SJL
groups (Figure 6a). Phase-contrast images verified an
increased density of astrocytes derived from G1H+/−
mice as compared to those from SJL mice (Figure 6b).
CCR2 immunoreactivity was intense and localized in
the cytoplasm of astrocytes derived from G1H+/− mice,
whereas it was only weak in astrocytes derived from SJL
mice (Figure 6c). To determine whether the MCP-1
-driven proliferation of astrocytes derived from G1H+/−
mice may be mediated by the specific receptor CCR2
stimulation, we evaluated the influence of the CCR2 an-
tagonist on the proliferation activity. As a consequence,
the levels were significantly reduced in the antagonist-




Morphological and quantitative evaluations for MCP-1 in
SOD1-mutated mice
It is known that MCP-1 is upregulated by oxidative
stress and inflammatory stimuli associated with several
pathological conditions including inflammatory and
autoimmune diseases and injuries [23,24]. Expression
patterns of MCP-1 in the central nervous system (CNS)
of postnatal mammalians have been well described.
Under physiological conditions, MCP-1 is constitutively
expressed in various types of cells, such as neurons,
astrocytes, microglia, and endothelial cells at a minimal
level. By contrast, it is highly induced in these cells or


































Figure 3 Immunohistochemical (a), immunoblot (b) and densitometric (c) analyses for CCR2 protein in the spinal cord of SJL and G1H
+/− mice sacrificed at presymptomatic (9 w), onset (12 w) and postsymptopatic (15 w) stages. Immunoreaction product deposits are
visualized by the avidin-biotin-immunoperoxidase complex method using 3,3’-diaminomenzidine tetrahydrochloride and hematoxylin as the
chromogen and counterstain, respectively, by light microscopy. Scale bar indicates 100 μm (a). Electrophoretic mobility (b) and optical density
(c) are compared between the postsymptomatic SJL and G1H+/− groups (n = 5 in each group). Two-way ANOVA provides P < 0.05. Posthoc
Bonferroni correction provides *P < 0.05 as compared to the SJL group.
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killer cells under pathological conditions such as trau-
matic injury, excitotoxicity, ischemia, inflammation, and
neurodegeneration [25-31].
As reviewed by McCombe and Henderson, emerging
evidence suggests the involvement of proinflammatory
mechanisms in ALS. Recent studies have demonstrated
increased expression levels of proinflammatory cytokines
and chemokines in activated microglia and reactive as-
trocytes in human ALS and its transgenic mouse models
[32,33]. Several studies indicated increased expression
levels of MCP-1 in the spinal cord of sporadic ALS
patients and SOD1-mutated mice [20]. Other investiga-
tors demonstrated the correlation between the cerebro-
spinal fluid MCP-1 levels and the disease progression
and severity of ALS [33,34].
In the present study, immunohistochemical analysis
revealed that MCP-1 determinants were mainly local-
ized in the cytoplasm of motor neurons in the spinal
cord of G93A mutant SOD1-overexpressing mice in
presymptomatic, onset, and postsymptomatic stages,
and were, in particular, more intense in vacuolatedneurons, than those in age-matched control mice.
RT-qPCR analysis of MCP-1 mRNA disclosed age-
related increases in G93A mice but not SJL mice,
and significant increases in young to old G93A mice
relative to the age-matched SJL mice. These observa-
tions are consistent with basic cell biological studies
indicating the production of MCP-1 in developing
human neurons and the NT2N human neuronal cell
line [35,36]. Consistent with our findings, Henkel
et al. reported increased levels of MCP-1 mRNA and
protein in motor neurons as well as reactive glial
cells in all stages of SOD1-mutated transgenic mouse
models of ALS [20]. Another study demonstrated
increased expression of MCP-1 in G93A mutant
SOD1-expressing microglia [37,38]. These observa-
tions indicate that MCP-1 could be produced by
motor neurons and glial cells in the spinal cord of
SOD1-mutated ALS mice. However, it should be con-
sidered with the caveat that the discrepancy of staining
intensity of MCP-1 in glial cells between the present

















Figure 4 Immunohistochemical observations of CCR2 protein in spinal cord ventral horns from G1H+/− mice sacrified at onset stage
(12 w). Localization of CCR2 immunoreactivity is verified by comparison with that of immunoreactivities for NeuN-immunoreactive (b) neurons,
GFAP-immunoreactive (e, h) astrocytes, and Iba1-immunoreactive (k) and CD11b-immunoreactive (n) microglia. CCR2 immunoreactivity is
detected with the two different antibodies sc-6228 (a, d, j, m) and PA1-27409 (g), respectively. Panels (c, f, i, l, o) indicate merged images in two
other panels of each line. Immunoreactive signals are detected by the double-labeled immunofluorescence method using secondary antibodies
conjugated with Cy3 (red) or FITC (green). Scale bar indicates 50 μm (a-o).
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Percentage of CCR2-immunoreactive cells (%)
in spinal cord lateral horns of 12 w G1H+/- mice









Figure 5 The percentage of CCR2-immunoreactive cells in neurons, astrocytes and microglia. Data obtained by the double-labeled
immunofluorescence method are compared by two-way ANOVA (P < 0.01) and posthoc Bonferroni correction (*P < 0.01 as compared to the
neuronal and microglial groups).
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SOD1-mutated mice
It is known that CCR2 acts as a membrane-bound re-
ceptor for the specific ligand MCP-1. CCR2 expression
is regulated at a low level under physiological condi-
tions [39], whereas it is upregulated by inflammatory
stimuli [40]. In several tissues other than the CNS,
CCR2 is constitutively expressed in monocytes and
macrophages on their cell surface. In the CNS, it has
been shown that CCR2 is expressed in microglia and
is upregulated under pathological conditions such as
multiple sclerosis, Alzheimer’s disease, and traumatic
brain injury [30,41,42]. In the present study, the double-
labeled immunofluorescence staining method revealed
that CCR2 immunoreactivity was intense and exclusively
localized in reactive astrocytes in the spinal cord of G93A
mice at onset and postsymptomatic stages but not SJL
mice at any stage. Several studies have provided evi-
dence that astrocytes express CCR2 as the following: (1)
MCP-1 and CCR2 are colocalized in astrocytes but not
microglia in rat models of experimental autoimmune
encephalomyelitis [43]; (2) MCP-1-driven astrocytic ac-
tivation is associated with CCR2 induction mediated
through activation of Akt and NF-κB [44]; (3) primary
cultures derived from human and simian astrocytes
express CCR2 mRNA and upregulate CCR2 by stimula-
tion of TNFα and IFNγ [40]; (4) cultured human astro-
cytes express CCR2 mRNA and protein and perform
chemotaxis and calcium influx in response to MCP-1
stimuli [45]. These observations support our data and
suggest that CCR2-expressing astrocytes survive and de-
monstrate astrocytosis occurring in the advanced stage of
a mutant SOD1 transgenic mouse of ALS.Under physiological conditions, astrocytes behave as
architectural components as well as participate in
neuroprotective mechanisms, forming morphological
and functional bases of the CNS. On the other hand,
astrocytes are involved in several pathological conditions
by exerting diverse effects on lesional microenviron-
ments [46]. In particular, astrocytes are implicated in
the pathomechanisms of neurological disorders, includ-
ing Alzheimer’s disease [47], Parkinson’s disease [48],
ALS [49,50], multiple sclerosis [51], and cerebral is-
chemia [52] via inflammatory responses. Relevantly, re-
cent evidence that selective excision of a mutated SOD1
gene in astrocytes inhibited microglial activation and
slowed disease progression suggests that mutant SOD1-
expressing astrocytes are responsible for non-cell
autonomous motor neuron death mediated through
inflammatory mechanisms on the basis of crosstalk to
microglia [53].
In the present study, we investigated CCR2 mRNA and
protein expression levels in the spinal cord of SJL and
G93A mice. In SJL mice, both the mRNA and protein
levels were constantly low at presymptomatic, onset, and
postsymptomatic stages. In G93A mice, CCR2 mRNA
levels were increased in presymptomatic and onset
stages but decreased in postsymptomatic stage, whereas
CCR2 protein levels were significantly higher in the
postsymptomatic G93A group than the age-matched
SJL group. The discrepancy in expression levels between
CCR2 mRNA and protein in postsymptomatic G93A
mice may reflect certain mechanisms based on SOD1
mutation. It has been shown that over 30% of genes
exhibit significantly divergent patterns of mRNA and
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Figure 6 (See legend on next page.)
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Figure 6 Effects of MCP-1 on proliferation activity of astrocytes derived from SJL and G1H+/− mice. Cultured astrocytes derived from SJL
(gray columns) and G1H+/− (black columns) mice are stimulated with recombinant murine MCP-1 (rmMCP-1) at concentrations of 0, 1, 10 and 50
ng/mL for 48 h, and the proliferation activity determined by a CCK8 kit is compared (a). The G1H+/− astrocytes are also stimulated with 10 ng/
mL rmMCP-1 in the presence (black columns) or absence (gray columns) of treatment with 10 μM CCR2 antagonist, and the proliferation activity
is compared (d). Two-way ANOVA provides P < 0.05 (a, d). Posthoc Bonferroni correction provides *P < 0.001 as compared to the MCP-1
-unstimulated SJL cell group, #P < 0.05 and §P < 0.01 as compared to the MCP-1-unstimulated G1H+/− group, and ¶P < 0.05 and †P < 0.01 as
compared to the CCR2 antagonist-untreated, rmMCP-1 concentration-matched G1H+/− groups. Morphological changes of cultured astrocytes
stimulated with 10 ng/mL rmMCP-1 are compared between the SJL and G1H+/− groups by phase-contrast images (b) and CCR2
immunocytochemistry detected by the immunofluorescence method using a secondary antibody conjugated with Cy3 (red) and DAPI (blue) as a
nuclear marker (c). Scale bars indicate 50 μm (b, c).
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in protein translation and degradation rates [54]. The
stability of CCR2 protein in G93A mice might be
changed by proteasome inhibition, which may occur in
the presence of oxidative stress originating in mutant
SOD1 toxicity [55]. CCR2 mRNA levels in human
monocytes are also downregulated by treatment with
bacteria-derived toxins such as lipopolysaccharide [56].
In cultured human monocytes, mRNA expression levels
of the major chemokine receptors, CCR2, CCR5, and
CXCR4 are upregulated by treatment with reactive
oxygen species, including hydrogen peroxide, and are
downregulated by treatment with antioxidant reagents
such as pyrrolidine dithiocarbamate and N-acetylcysteine,
although these treatments do not influence the stability of
CCR2 protein on the cell surface [57]. Irradiation-
triggered oxidative stress induces CCR2 protein ex-
pression associated with the lipid peroxidation product
4-hydroxy-2-nonenal in mouse hippocampi [58]. More-
over, a recent study indicated reducedCCR2mRNA levels
in circulatingmonocytes from sporadic ALS patients [22].
These observations suggest that altered redox states in
G93A mice contribute to downregulation of CCR2 mRNA
andupregulationor stabilizationofCCR2protein, leading to
an increased innate immune response to SOD1 mutation-
relatedoxidativestress.
MCP-1 induces proliferation of astrocytes derived from
SOD1-mutated mice
It is known that neuroinflammation based on activation of
astrocytes and microglia diminishes survival of motor
neurons to exacerbate disease progression of ALS [4]. Ac-
cumulating evidence suggests that astrocytes expressing
mutant SOD1 are highly toxic to motor neurons. In par-
ticular, recent studies indicated that cultured astrocytes
expressing mutant SOD1 demonstrated increased prolifer-
ation activity and reduced glutamate transporter-1 expres-
sion. The mutant SOD1-expressing astrocytes seems to
produce certain soluble factors, which are toxic to motor
neurons and activate microglia to induce motor neuron
death [50,59]. In the present study, the basic and MCP-1
-driven levels of proliferation activity and CCR2 expres-
sion were significantly increased in cultured astrocytesderived from G93A mice as compared to those from SJL
mice. Moreover, the MCP-1-driven proliferation activity
in the G93A astrocytes was suppressed by a CCR2 antag-
onist. Given the age-related increase in MCP-1 mRNA
levels in the spinal cord of G93A mice, it is evident that
astrocytes carrying a transgene for mutant SOD1 play a
pivotal role in the disease progression via MCP-1/CCR2-
mediated signaling.
Conclusions
Taken together, we here showed a significant upregulation
of MCP-1 and CCR2 in the spinal cord of G93A mutant
human SOD1-overexpressing mice relative to nontrans-
genic littermates. This upregulation occurred even if in
presymptomatic stage and was then enhanced along
with aging. While MCP-1 was mainly expressed in
motor neurons, CCR2 was mainly expressed in reactive
astrocytes. These results provide in vivo evidence that
MCP-1, released from the lesional cells including motor
neurons, selectively stimulates CCR2-expressing astro-
cytes in a paracrine manner, leading to cell activation
such as proliferation. Our results suggest that astrocytic
activation driven by the MCP-1/CCR2 signaling path-
way is a newly identified target of ALS therapies. Finally,
determining the precise role of the MCP-1/CCR2 sig-




The present study was approved by the Animal Research
Ethics Committee of Tokyo Women’s Medical University.
Mice overexpressing a transgene for G93A mutant human
SOD1 [high expresser G1H line (G1H+/−) mice] [60] and
nontransgenic littermates [background strain of Jackson
Laboratory line (SJL) mice] were obtained from Jackson La-
boratory (Bar Harbor, ME, USA). We maintained G1H+/−
mice by mating transgenic males with nontransgenic fe-
males. Transgenic offsprings were genotyped by detecting
human SOD1 protein in addition to mouse SOD1 protein
using immunoblots as described before [5], and
nontransgenic littermates were used as negative controls of
the genetic background. After birth, G1H+/− mice
Table 1 Primer sets for reverse transcription-quantitative
polymerase chain reaction
Gene Sequence Amplicon (bp)
MCP-1 F: 5′-GCATCCACGTGTTGGCTCA-3′ 95
R: 5′-CTCCAGCCTACTCATTGGGATCA-3′
CCR2 F: 5′-ACAGCTCAGGATTAACAGGGACTTG-3′ 129
R: 5′-ACCACTTGCATGCACACATGAC-3′
GAPDH F: 5′-TGTGTCCGTCGTGGATCTGA-3′ 150
R: 5′-TTGCTGTTGAAGTCGCAGGAG-3′
Abbreviations: MCP-1, monocyte chemoattractant protein-1; CCR2, CC
chemokine receptor 2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; F,
forward; R, reverse; bp, base pair.
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began to show clinical symptoms such as weakness and
tremor prominent in their hindlimbs at around 12 w
(onset stage), developed progressive gait disturbance
reminiscent of human ALS (postsymptomatic stage),
and died of respiratory failure or an eating disability by
20 w. Both G1H+/− and SJL mice were divided into the
presymptomatic, onset, and postsymptomatic groups,
and were sacrificed under anesthesia with ether ethanol
at the respective periods (9 w, 12 w, and 15 w) to obtain
lumbar spinal cords, including the main lesions in the
mouse ALS-like disease.
RT-qPCR analysis
The primer sets used in RT-qPCR are summarized in
Table 1. All of them were purchased from Takara. Total
RNA was extracted from freshly frozen materials of
lumbar spinal cords using the RNeasy Lipid Tissue Mini
kit (Qiagen, Valencia, CA, USA), and in turn were used
for RT to obtain cDNA using the Prime Script RT-PCR
kit (Takara, Tokyo, Japan). qPCR was performed using
cDNA derived from 50 ng of total RNA, primer sets at a
final concentration of 50 pM, and SYBR Premix Ex Taq
II (Takara) according to the manufacturer’s instructions.
Amplification profiles consisted of 95°C for 10 sec (ini-
tial denaturing), followed by 45 cycles at 95°C for 5 secTable 2 Primary antibodies used for
immunohistochemistry
Antigen Species Dilution Cat. No. Source
MCP-1 Rabbit 1:100 ab7202 Abcam
CCR2 Goat 1:100 sc-6228 SCB
CCR2 Goat 1:100 PA1-27409 Thermo
NeuN Mouse 1:300 MAB377 Chemicon
GFAP Rabbit 1:500 z0334 Dako
CD11b Rat 1:50 ab8878 Abcam
Iba1 Rabbit 1:200 019-19741 Wako
Abbreviations: MCP-1, monocyte chemoattractant protein-1; CCR2, CC
chemokine receptor 2; GFAP, glial fibrillary acidic protein; Iba1, ionized
calcium-binding adaptor molecule 1; SCB, Santa Cruz Biotechnology.(denaturing), 55°C for 10 sec (annealing) and 72°C for
20 sec (extension). At the end of each run, a melting
point analysis was performed to validate the specificity
of the PCR products. The quality of the PCR products
was also confirmed by ethidium bromide-supplemented
agarose gel electrophoresis. House-keeping gene for
glyceraldehyde dehydrogenase (GAPDH) was used to
normalize transcription levels of MCP-1 and CCR2. The
normalized data were compared between the different
groups (n = 6 in each group).
Immunohistochemical analysis
The primary antibodies employed in immunohistochemistry
are summarized in Table 2. NeuN and glial fibrillary acidic
protein (GFAP) were used as markers for neurons and as-
trocytes, respectively. Both CD11b and Iba1 were used as
markers for microglia. For immunohistochemistry, mice
were perfused with phosphate-buffered saline, pH 7.5 (PBS)
followed by 3% paraformaldehyde in PBS. Spinal cords were
subsequently removed and processed for making paraffin-
embedded materials or optimal cutting temperature
compound-embedded frozen materials. Multiple 7-μm-thick
paraffin-embedded sections and 10-μm-thick frozen sections
were used for immunohistochemical staining. Paraffin-
embedded sections were deparaffinized, and frozen sections
were air-dried. These sections were subsequently rehydrated,
quenched for 20 min in 3% hydrogen peroxide in PBS,
pretreated for 30 min at room temperature with 3% bo-
vine serum albumin in PBS, and in turn incubated over-
night at 4°C with a primary antibody in PBS containing
0.1% Triton X-100 and 1% of normal horse serum. Anti-
body binding was visualized by the avidin-biotin
-immunoperoxidase complex (ABC) method using the ap-
propriate Vectastain ABC kit (Vector Laboratories, Burlin-
game, CA, USA) according to the manufacturer’s
instructions. 3,3’-Diaminobenzidine tetrahydrochloride was
the chromogen, and hematoxylin, the counterstain.
Tissue distribution of MCP-1 and CCR2 was roughly
verified by comparison with consecutive sections stained
with hematoxylin-eosin (H&E). Immunohistochemical
localization of CCR2 was precisely identified by the
double-labeled immunofluorescence method. In brief,
sections were incubated simultaneously with the primary
antibodies against a target substance and a cell marker
followed by the secondary antibodies such as Cy3-
conjugated donkey anti-goat IgG and fluorescein isothio-
cyanate (FITC)-conjugated donkey anti-mouse, rat, or
rabbit IgG (each diluted 1:200; Jackson Immunoresearch
Laboratory, West Grove, PA, USA). DAPI was use as a
nuclear stain. Immunoreaction product deposits were
observed and recorded with a fluorescence microscope
(Nikon ECLIPSE TS100; Nikon, Tokyo, Japan) or a con-
focal laser microscope (LSM 510 Meta, Carl Zeiss, Jena,
Germany). The percentage of CCR2-immunoreactive
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horns was verified by NIH image J software.
Immunoblot analysis
Resected fresh mouse spinal cords were stored at −80°C
until use. For immunoblotting, frozen spinal cord materials
were homogenized in 20 mM Tris-buffered saline, pH 8.5
(TBS), supplemented with 5 mM ethylenediaminetetraacetic
acid (EDTA), 10% glycerol, 1% Triton X-100, 0.1% sodium
dodecyl sulfate (SDS), 0.5% sodium deoxycholic acid, 1 mM
phenylmethylsulfonylfluoride, and a protease inhibitor cock-
tail Complete Mini (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s instructions. The
homogenate was then centrifuged at 12,500 g for 15 min to
obtain supernatant containing total protein extracts. Protein
concentration was determined by the Bradford method [61].
Total protein extracts were boiled for 10 min at 100°C with
an equal volume of Laemli’s buffer containing 0.05%
bromophenol blue, and were used for 12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Aliquots of sam-
ples (70 μg of protein per lane) were loaded and separated
in a gel, were and electroblotted onto a polyvinylidene
difluoride (PVDF) membrane (Millipore, Billerica, MA,
USA). After transfer, PVDF membranes were pretreated
overnight at 4°C in 100 mM TBS, containing 0.1% Tween-
20 and 5% skim milk, and then incubated for 1 h at room
temperature with the anti-CCR2 antibody (Santa Cruz) at a
dilution of 1:1,000 or mouse anti-β-actin antibody (Sigma-
Aldrich, St. Louis, MO, USA) at a dilution of 1:2,000. Blots
processed with omission of the primary antibodies served as
negative reaction controls. Immunoreactive signals were vi-
sualized by the chemiluminescence method using the ap-
propriate ECL detection system kit (Amersham,
Buckinghamshire, UK), scanned with a Light-Capture
Cooled Camera system (ATTO, Tokyo, Japan), and
imported onto a personal computer. Optical density was
then quantified with NIH Image J software. In each sam-
ple, immunoreactive signals for CCR2 were normalized by
those for β-actin, and the CCR2/β-actin optical density ra-
tio was compared between the different groups.
Cell culture and proliferation assay
Astrocytes were grown in primary culture as described pre-
viously [62]. Briefly, the cerebral hemispheres of newborn
SJL and G1H+/− mice were removed, the meninges were
carefully removed off, and the cerebral tissues were dissoci-
ated with trypsin. The dissociated cells were seeded at 1.4
× 104 viable cells/cm2 in a plastic culture flask and grown
for 2 weeks in Dulbecco’s modified Eagle’s medium with
20% F-12 and 10% fetal bovine serum at 37°C in a 5%CO2
incubator. Before experiments, immunocytochemistry con-
firmed that over 95% of the cells were stained positively for
the astrocytic marker GFAP. For proliferation assay, cells
were plated on 96-well plates (4 × 103 cells/well) andallowed to adhere for 24 h at 37°C. The cultures were then
stimulated with recombinant murine MCP-1 (rmMCP-1;
Pepro Tech, Rocky Hill, NJ, USA) at concentrations of 0, 1,
10 and 50 ng/mL for 48 h in the presence or absence of a
CCR2 antagonist (Calbiochem, La Jolla, CA, USA) at a
final concentration of 10 μM, followed by incubation with
a Cell Counting Kit-8 (CCK-8; Dojindo Laboratories,
Kumamoto, Japan) solution at a final concentration of
10 μM, and the cells were incubated for 2 h at 37°C,
according to the manufacturer’s instructions. The optical
absorbance at 450 nm for each sample was measured using
a microplate reader (Bio-Lad Laboratories, Richmond, CA,
USA).
Statistics
Data were compared between three or more groups by
two-way analysis of variance (ANOVA) followed by
posthoc Bonferroni correction. Significance was consid-
ered in the case of P-value < 0.05.
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